BC Innovations | Feb 17, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Addiction Nicotinic acetylcholine receptor a5 (CHRNA5) Studies in rodents suggest that agonizing CHRNA5 could help treat nicotine addiction. Previous genomewide association studies have shown...
BC Innovations | Apr 9, 2009
Targets & Mechanisms

Susceptibility loci for COPD

A genomewide association study from GlaxoSmithKline plc and Duke University has identified two new susceptibility loci for COPD that might not only help assess disease risk, but also lead to new therapeutic targets. 1 A...
BC Innovations | Apr 2, 2009
Distillery Therapeutics

Indication: Pulmonary disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Chronic obstructive pulmonary disease (COPD) Cholinergic receptor, nicotinic, a3 (CHRNA3); CHRNA5; hedgehog interacting protein (HHIP) Genomewide association studies helped identify...
Items per page:
1 - 3 of 3